Xilio Therapeutics Inc. has reported its financial results for the second quarter ended June 30, 2025. The company reported a collaboration and license revenue of $8.1 million, a significant increase from $2.4 million in the same quarter of the previous year. This rise was attributed to revenue recognized in connection with Xilio's collaborations with AbbVie and Gilead, compared to the previous year's revenue which was linked solely to Gilead. The net loss for the quarter stood at $15.8 million, compared to a net loss of $13.9 million in the corresponding quarter of 2024. General and administrative expenses also saw an increase, totaling $7.1 million, up from $5.8 million in the prior year, primarily driven by higher professional and consulting fees and increased personnel-related costs. Xilio provided a financial outlook indicating that its cash and cash equivalents, which amounted to $121.6 million as of June 30, 2025, are expected to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026. This cash position was bolstered by $47.0 million in net proceeds from a follow-on public offering in June 2025. Significant corporate updates included the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors, and the closing of a follow-on public offering of prefunded warrants and accompanying common stock warrants. This offering, which included new investments from Coastlands Capital and Frazier Life Sciences, along with participation from Gilead Sciences, Inc. and other investors, resulted in initial gross proceeds of approximately $50.0 million. If all issued warrants are exercised, Xilio stands to receive up to an additional $100.0 million by the second half of 2026.